Trials / Completed
CompletedNCT01276106
Study of AC-201 in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase II Study of AC-201 in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 259 (actual)
- Sponsor
- TWi Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a 24-week randomized placebo-controlled study to investigate the effect of an oral IL-1beta inhibitor AC-201 in patients with type 2 diabetes mellitus already treated on different background diabetes therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AC-201, 25mg | Capsule, 25mg BID |
| DRUG | AC-201, 50mg | Capsule, 50mg BID |
| DRUG | AC-201, 75mg | Capsule, 75mg BID |
| DRUG | Placebo | Placebo BID |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2012-02-01
- Completion
- 2012-03-01
- First posted
- 2011-01-13
- Last updated
- 2018-05-22
- Results posted
- 2014-11-18
Locations
21 sites across 2 countries: United States, Taiwan
Source: ClinicalTrials.gov record NCT01276106. Inclusion in this directory is not an endorsement.